αV β6 Integrin: An Intriguing Target for COVID-19 and Related Diseases.
Kelly BugattiPublished in: Chembiochem : a European journal of chemical biology (2021)
The outbreak of SARS-CoV-2 has been an extraordinary event that constituted a global health emergency. As the novel coronavirus is continuing to spread over the world, the need for therapeutic agents to control this pandemic is increasing. αV β6 Integrin may be an intriguing target not only for the inhibition of SARS-CoV-2 entry, but also for the diagnosis/treatment of COVID-19 related fibrosis, an emerging type of fibrotic disease which will probably affect a significant part of the recovered patients. In this short article, the possible role of this integrin for fighting COVID-19 is discussed on the basis of recently published evidence, showing how its underestimated involvement may be interesting for the development of novel pharmacological tools.
Keyphrases
- sars cov
- global health
- respiratory syndrome coronavirus
- coronavirus disease
- public health
- end stage renal disease
- ejection fraction
- newly diagnosed
- emergency department
- healthcare
- cell adhesion
- prognostic factors
- idiopathic pulmonary fibrosis
- systemic sclerosis
- systematic review
- patient reported outcomes
- smoking cessation
- drug induced